{"nctId":"NCT00107978","briefTitle":"Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus","startDateStruct":{"date":"2005-02"},"conditions":["Staphylococcal Skin Infection"],"count":1035,"armGroups":[{"label":"Telavancin","type":"EXPERIMENTAL","interventionNames":["Drug: Telavancin"]},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vancomycin"]}],"interventions":[{"name":"Telavancin","otherNames":["VIBATIV","TD-6424"]},{"name":"Vancomycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:\n\n  * major abscess requiring surgical incision and drainage;\n  * infected burn (see exclusion criteria for important qualifications);\n  * deep/extensive cellulitis;\n  * infected ulcer (see exclusion criteria for important qualifications);\n  * wound infections\n* Patients must be expected to require at least 7 days of intravenous antibiotic treatment.\n\nExclusion Criteria:\n\n* Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy\n* Burns involving \\> 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Response","description":"The Clinical Response for each patient was determined by the investigator by assessing the patient's clinical signs \\& symptoms compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null},{"groupId":"OG001","value":"364","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":503},"commonTop":["Dysgeusia","Nausea","Headache","Pruritis","Urine Abnormality"]}}}